Sublingual or subcutaneous immunotherapy for allergic rhinitis?

Area of Science:

• Immunology
• Allergology
• Clinical Medicine

Background:

• Allergen immunotherapy modifies the underlying cause of allergic rhinitis (AR), offering long-term benefits unlike symptomatic treatments.
• Subcutaneous immunotherapy (SCIT) is the established standard, while sublingual immunotherapy (SLIT) is a recognized safe and effective alternative.
• Previous reviews indicated efficacy for seasonal AR but were less conclusive for perennial AR.

Purpose of the Study:

• To appraise the comparative efficacy and safety of SCIT versus SLIT for allergic rhinitis.
• To evaluate evidence from systematic reviews, meta-analyses, and recent large-scale randomized controlled trials.
• To provide guidance on treatment selection pending definitive head-to-head comparative trials.

Main Methods:

• Indirect evidence appraisal from Cochrane reviews and meta-analyses.
• Analysis of recent well-powered double-blind, randomized controlled trials (RCTs) versus placebo.
• Inclusion of limited direct evidence from randomized blind head-to-head comparisons.

Main Results:

• Recent large trials show both SCIT and SLIT reduce symptoms and rescue medication use in seasonal and perennial AR.
• Evidence suggests comparable efficacy between SCIT and SLIT for AR.
• The overall balance of efficacy and side effects currently places patients in equipoise regarding treatment choice.

Conclusions:

• Both SCIT and SLIT are effective treatment options for allergic rhinitis.
• Treatment decisions may depend on local product availability and individual patient preference.
• Further definitive comparative trials are needed to establish clear superiority between SCIT and SLIT.